Literature DB >> 22020294

MEK5/ERK5 pathway: the first fifteen years.

Barbara A Drew1, Matthew E Burow, Barbara S Beckman.   

Abstract

While conventional MAP kinase pathways are one of the most highly studied signal transduction molecules, less is known about the MEK5 signaling pathway. This pathway has been shown to play a role in normal cell growth cycles, survival and differentiation. The MEK5 pathway is also believed to mediate the effects of a number of oncogenes. MEK5 is the upstream activator of ERK5 in many epithelial cells. Activation of the MEK-MAPK pathway is a frequent event in malignant tumor formation and contributes to chemoresistance and anti-apoptotic signaling. This pathway may be involved in a number of more aggressive, metastatic varieties of cancer due to its role in cell survival, proliferation and EMT transitioning. Further study of this pathway may lead to new prognostic factors and new drug targets to combat more aggressive forms of cancer.
Copyright © 2011 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22020294      PMCID: PMC3954580          DOI: 10.1016/j.bbcan.2011.10.002

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  113 in total

1.  Contribution of the ERK5/MEK5 pathway to Ras/Raf signaling and growth control.

Authors:  J M English; G Pearson; T Hockenberry; L Shivakumar; M A White; M H Cobb
Journal:  J Biol Chem       Date:  1999-10-29       Impact factor: 5.157

Review 2.  Mammalian MAP kinase signalling cascades.

Authors:  L Chang; M Karin
Journal:  Nature       Date:  2001-03-01       Impact factor: 49.962

3.  A conserved docking motif in MAP kinases common to substrates, activators and regulators.

Authors:  T Tanoue; M Adachi; T Moriguchi; E Nishida
Journal:  Nat Cell Biol       Date:  2000-02       Impact factor: 28.824

4.  MEKK3 directly regulates MEK5 activity as part of the big mitogen-activated protein kinase 1 (BMK1) signaling pathway.

Authors:  T H Chao; M Hayashi; R I Tapping; Y Kato; J D Lee
Journal:  J Biol Chem       Date:  1999-12-17       Impact factor: 5.157

5.  Protein kinase SGK mediates survival signals by phosphorylating the forkhead transcription factor FKHRL1 (FOXO3a).

Authors:  A Brunet; J Park; H Tran; L S Hu; B A Hemmings; M E Greenberg
Journal:  Mol Cell Biol       Date:  2001-02       Impact factor: 4.272

6.  Differential regulation of mitogen-activated protein kinases ERK1/2 and ERK5 by neurotrophins, neuronal activity, and cAMP in neurons.

Authors:  J E Cavanaugh; J Ham; M Hetman; S Poser; C Yan; Z Xia
Journal:  J Neurosci       Date:  2001-01-15       Impact factor: 6.167

7.  Multiple mitogen-activated protein kinase signaling pathways connect the cot oncoprotein to the c-jun promoter and to cellular transformation.

Authors:  M Chiariello; M J Marinissen; J S Gutkind
Journal:  Mol Cell Biol       Date:  2000-03       Impact factor: 4.272

8.  Signaling from G protein-coupled receptors to ERK5/Big MAPK 1 involves Galpha q and Galpha 12/13 families of heterotrimeric G proteins. Evidence for the existence of a novel Ras AND Rho-independent pathway.

Authors:  S Fukuhara; M J Marinissen; M Chiariello; J S Gutkind
Journal:  J Biol Chem       Date:  2000-07-14       Impact factor: 5.157

Review 9.  The role of NF-kappaB/IkappaB proteins in cancer: implications for novel treatment strategies.

Authors:  S A Schwartz; A Hernandez; B Mark Evers
Journal:  Surg Oncol       Date:  1999-11       Impact factor: 3.279

10.  Targeted inactivation of Mapk4 in mice reveals specific nonredundant functions of Erk3/Erk4 subfamily mitogen-activated protein kinases.

Authors:  Justine Rousseau; Sonia Klinger; Adeline Rachalski; Benjamin Turgeon; Paul Déléris; Erika Vigneault; Jean-François Poirier-Héon; Maria Antonietta Davoli; Naguib Mechawar; Salah El Mestikawy; Nicolas Cermakian; Sylvain Meloche
Journal:  Mol Cell Biol       Date:  2010-10-18       Impact factor: 4.272

View more
  70 in total

1.  Increased IGF-IEc expression and mechano-growth factor production in intestinal muscle of fibrostenotic Crohn's disease and smooth muscle hypertrophy.

Authors:  Chao Li; Kent Vu; Krystina Hazelgrove; John F Kuemmerle
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2015-10-01       Impact factor: 4.052

2.  A Chemical Probe Strategy for Interrogating Inhibitor Selectivity Across the MEK Kinase Family.

Authors:  Kristine K Deibler; Rama K Mishra; Matthew R Clutter; Aleksandar Antanasijevic; Raymond Bergan; Michael Caffrey; Karl A Scheidt
Journal:  ACS Chem Biol       Date:  2017-03-20       Impact factor: 5.100

3.  Discovery and characterization of an iminocoumarin scaffold as an inhibitor of MEKK2 (MAP3K2).

Authors:  Syed Ahmad; Valentine R St Hilaire; Srinivasa R Dandepally; Gary L Johnson; Alfred L Williams; John E Scott
Journal:  Biochem Biophys Res Commun       Date:  2018-01-05       Impact factor: 3.575

4.  KRAS Suppression-Induced Degradation of MYC Is Antagonized by a MEK5-ERK5 Compensatory Mechanism.

Authors:  Angelina V Vaseva; Devon R Blake; Thomas S K Gilbert; Serina Ng; Galen Hostetter; Salma H Azam; Irem Ozkan-Dagliyan; Prson Gautam; Kirsten L Bryant; Kenneth H Pearce; Laura E Herring; Haiyong Han; Lee M Graves; Agnieszka K Witkiewicz; Erik S Knudsen; Chad V Pecot; Naim Rashid; Peter J Houghton; Krister Wennerberg; Adrienne D Cox; Channing J Der
Journal:  Cancer Cell       Date:  2018-11-12       Impact factor: 31.743

5.  Nuclear ERK5 inhibits progression of leukemic monocytes to macrophages by regulating the transcription factor PU.1 and heat shock protein HSP70.

Authors:  Ruifang Zheng; George P Studzinski
Journal:  Leuk Lymphoma       Date:  2016-10-17

6.  MEK5-ERK5 pathway associates with poor survival of breast cancer patients after systemic treatments.

Authors:  Mariska Miranda; Esdy Rozali; Kum Kum Khanna; Fares Al-Ejeh
Journal:  Oncoscience       Date:  2015-02-20

Review 7.  Non-'classical' MEKs: A review of MEK3-7 inhibitors.

Authors:  Ada J Kwong; Karl A Scheidt
Journal:  Bioorg Med Chem Lett       Date:  2020-04-23       Impact factor: 2.823

8.  Epitope-guided engineering of monobody binders for in vivo inhibition of Erk-2 signaling.

Authors:  Jasdeep K Mann; Jordan F Wood; Anne Fleur Stephan; Emmanuel S Tzanakakis; Denise M Ferkey; Sheldon Park
Journal:  ACS Chem Biol       Date:  2012-12-18       Impact factor: 5.100

9.  IFN-γ-inducible antiviral responses require ULK1-mediated activation of MLK3 and ERK5.

Authors:  Diana Saleiro; Gavin T Blyth; Ewa M Kosciuczuk; Patrick A Ozark; Beata Majchrzak-Kita; Ahmet D Arslan; Mariafausta Fischietti; Neha K Reddy; Curt M Horvath; Roger J Davis; Eleanor N Fish; Leonidas C Platanias
Journal:  Sci Signal       Date:  2018-11-20       Impact factor: 8.192

10.  An alternative mode of CD43 signal transduction activates pro-survival pathways of T lymphocytes.

Authors:  Maria Elena Bravo-Adame; Rosario Vera-Estrella; Bronwyn J Barkla; Cecilia Martínez-Campos; Angel Flores-Alcantar; Jose Pablo Ocelotl-Oviedo; Gustavo Pedraza-Alva; Yvonne Rosenstein
Journal:  Immunology       Date:  2016-10-12       Impact factor: 7.397

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.